Dupilumab associated with "highly favorable" outcomes in Type 2 Chronic Rhinosinusitis

The critical points of the study are:

• A total of 30 patients were included.

• Serum sample collection was done on day 0 and 30 days of treatment.

• Olink was used to perform proteomic analyses.

• On day 7, there was an improvement in SinoNasalOutcomeTest-20 (SNOT-20) scores and the total nasal polyp score. The p-value was significant (p<0.05).

• A sensitivity of 86% with an improvement of 2.5 points was recorded (during the first visit).

• In comparison to HC, significant changes were reported in the proteomic analyses.

Dr. Michael B Soyka from the Department of Otorhinolaryngology at Head and Neck Surgery University and University Hospital Zurich said, "We identified OPG from the serum of patients who were treated with dupilumab. It is a significant finding which may contribute as the "predictor" of the clinical outcome in such patients.

Dr. Fabio S. Ryser from the Department of Immunology at University and University Hospital, Zurich, added, "We confirmed the predictive value of OPG in the second cohort."

The final conclusion from the researchers was, "we reported a highly associated favorable outcome after one week of dupilumab treatment. T2CRS-specific protein (dysregulated) in such patients can be identified with proteomic analyses, which are highly sensitive. Before initiating therapy in such patients, serum OPG should be detected to predict the treatment outcome."

References:

• Predicting Dupilumab Treatment Outcome in Patients with Primary diffuse Type 2 Chronic Rhinosinusitis.Michael B. Soyka,Fabio S. Ryser,Catrin Brühlmann,Danielle Fehr,Jacqueline Dülgeroglu,Peter Schmid-Grendelmeier,Marie-Charlotte Brüggen,Urs C. Steiner First published: 26 September 2022
• https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-rhinosinusitis-nasal-polyps